search
Back to results

Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study (PROMIZING)

Primary Purpose

Critically Ill, Acute Respiratory Failure

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
PSV ventilation strategy
PAV+ ventilation strategy
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Critically Ill focused on measuring Proportional Assist Ventilation, Pressure Support Ventilation, Weaning

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

A staged enrolment process will be used to identify patients eligible to be enrolled and randomized in the study. At each stage of the enrolment process, a patient must meet inclusion criteria and not meet exclusion criteria in order to pass. To progress to the next stage, patients must continue to pass criteria from the prior stages. After enrolment, there are also specific tests to perform (with pass/fail criteria) to determine eligibility to be randomized.

A. SCREENING INCLUSION CRITERIA:

  • A1. Age 18 years or older
  • A2. Intubated and receiving any mode of invasive mechanical ventilation ≥ 24 hours

A. SCREENING EXCLUSION CRITERIA:

  • A3. Anticipating withdrawal of life support and/or shift to palliation as the goal of care
  • A4. Severe central neurologic disorder (eg. Hemorrhage, stroke, tumour) causing elevated intracranial pressure, or impaired control of breathing, or requiring specific ventilator adjustments (i.e. To attain specific CO2 target) or requiring neurosurgical intervention
  • A5. Known or suspected severe or progressive neuromuscular disorder likely to result in prolonged or chronic ventilator dependence (eg. Guillain-Barré syndrome, Myasthenia Gravis, ALS, MS, high spinal cord injury, kyphoscoliosis or other restrictive disorder) (Note that obesity hypoventilation syndrome that may be managed with nocturnal non-invasive ventilation is NOT an exclusion under A5)
  • A6. Severe COPD: Baseline daytime hypercapnea (pCO2> 50 mmHg) OR GOLD 4 airflow limitation (FEV1<30% predicted) OR MRC class 4 symptoms ("I am too breathless to leave the house" OR "I am breathless when dressing")
  • A7. Broncho-pleural fistula
  • A8. Tracheostomy present at ICU admission for the purpose of chronic or prolonged mechanical ventilation (>21 days). (Note that a patient who was endotracheally intubated for acute respiratory failure and received a tracheostomy during their ICU admission, prior to enrolment, is not excluded under A8).
  • A9. Current enrolment in a confounding study, as assessed by the steering committee
  • A10. Previous randomization in the PROMIZING Study
  • A11. Severe, end-stage, irreversible respiratory or cardiac disease (e.g. interstitial lung disease, pulmonary fibrosis, cardiomyopathy, valvulopathy) likely to result in prolonged or chronic ventilator dependence /unlikely to wean from mechanical ventilation [Note: patients who are candidates for intervention to treat the underlying respiratory/cardiac disease (e.g. lung transplant, heart transplant, cardiac surgery) may be re-evaluated once intervention is complete and they no longer meet criteria A11.]

B. ENROLMENT INCLUSION CRITERIA:

  • B1. Ability or potential ability to trigger ventilator breaths (i.e. not receiving neuromuscular blockade).
  • B2. On Assist/Control volume-cycled ventilation: Technically satisfactory plateau pressure ≤ 30 cm H2O (see Operations Manual) OR On Assist/Control pressure-controlled ventilation or similar mode: Pressure control plus PEEP ≤ 30 cm H2O OR On Pressure Support ventilation: Pressure support plus PEEP ≤ 30 cm H2O OR On Proportional Assist ventilation: PAV gain <85%
  • B3. PaO2 ≥ 60 mmHg or SpO2 ≥ 90% on FiO2 ≤ 0.60 and PEEP ≤ 15 cm H2O
  • B4. Metabolic disorders corrected: pH ≥7.32
  • B5. Stable hemodynamic status: stable or decreasing doses of vasopressors for ≥6 hours
  • B6. Anticipate ongoing need for ventilation >24 hours

B. ENROLMENT EXCLUSION CRITERIA:

  • B7. Extubated
  • B8. Died
  • B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% for ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). (Note (1): that it is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients on ECMO.)
  • B10. Patient transferred to a non-participating centre

B. ENROLMENT DEFERRAL CRITERIA:

  • B11. Plan to extubate/discontinue mechanical ventilation within <24 hours (Reassess within 24 hours)
  • B12. Patient currently on ECMO (Reassess patient once off ECMO)
  • C9: Plan for surgery or complex procedure that will require full ventilation to be done prior to attempting extubation (e.g. Procedure requiring neuromuscular blockade and/or heavy sedation, such that patient would be apneic, or not be able to trigger ventilator) (Reassess after surgery/procedure complete)

C. PRESSURE SUPPORT TRIAL INCLUSION CRITEIRA:

  • C2. Upon review of Screening and Enrolment criteria (A and B), the patient still passes.
  • C3. Treating physician has provided verbal consent to proceed with standardized tests and randomization if eligibility criteria are met.

C. PRESSURE SUPPORT TRIAL DEFERRAL CRITERIA:

  • C6. High dose vasopressor requirements (i.e. epinephrine or norepinephrine >0.5 ug/kg/min or equivalent) OR patient requiring an increase in dose of vasopressor within 6 hrs
  • C7. Active cardiac ischemia (dynamic ST changes on monitor or ECG within 6 hours)
  • C8. Unstable arrhythmias (HR>140 or <50) with clinical signs of low cardiac output or or SBP<80 mmHg
  • C10. Receiving a "strict lung protective" ventilation strategy for ARDS (eg. Order on chart to keep Vt ≤6 mL/kg PBW)

C. PRESSURE SUPPORT TRIAL EXCLUSION CRITERIA:

• C12. Treating physician has declined consent

D. WEANING CRITERIA:

  • D1. SpO2≥ 90% on FiO2 ≤0.40 and PEEP ≤8 cmH2O
  • D2. pH ≥7.32
  • D3. Vasopressor requirements no higher than norepinephrine 0.1 ug/kg/min or equivalent.

In the final stage (E), patients will be considered eligible for randomization if the following criteria are met.

E. RANDOMIZATION INCLUSION CRITERIA:

  • C1. Patient/SDM has provided consent OR Plan to obtain deferred consent as Patient incapable and no SDM available to provide consent within the randomization window
  • E1. Upon review of Criteria A, B, and C, the patient still passes and the patient has passed the PST.
  • E2. Does not meet Weaning Criteria OR Fails the ZERO CPAP Trial OR Fails the SBT

E. RANDOMIZATION EXCLUSION CRITERIA:

  • B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). Note (1): It is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients while on ECMO
  • C4. Patient/SDM has declined consent
  • C5. Patient incapable and no SDM available to provide consent (not applicable if plan to obtain deferred consent)
  • E3. Passed SBT on t-piece, FiO2 0.40 for 30-120 minutes
  • E4. Approval withdrawn (by physician or patient/SDM)

Sites / Locations

  • El Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"Recruiting
  • Royal Columbian Hospital
  • Kingston General HospitalRecruiting
  • London Health Sciences Centre - University HospitalRecruiting
  • Victoria HospitalRecruiting
  • Sunnybrook Hospital - Health Sciences CentreRecruiting
  • Mount Sinai Hospital
  • North York General HospitalRecruiting
  • St. Michael's HospitalRecruiting
  • UHN- Toronto General HospitalRecruiting
  • UHN- Toronto Western HospitalRecruiting
  • Centre hospitalier de l'Université de Montréal (CHUM)Recruiting
  • Hôpital du Sacré-Cœur de Montréal
  • Royal Victoria HospitalRecruiting
  • Institut Universitaire de cardiologie et de pneumologie de Quebec
  • Centre Hospitalier Universitaire (CHU) de AngersRecruiting
  • Centre Hospitalier Intercommunal de Créteil
  • Hôpital Henri Mondor (Assistance Publique-Hôpitaux de Paris)Recruiting
  • Centre Hospitalier Universitaire (CHU) de Nice
  • Hôpital Universitaire Pitié-SalpêtrièreRecruiting
  • Centre Hospitalier Universitaire (CHU) de RouenRecruiting
  • University Hospital of HeraklionRecruiting
  • University Hospital of FerraraRecruiting
  • San Giovanni Battista University HospitalRecruiting
  • King Abdulaziz Medical CityRecruiting
  • Hospital de Sant PauRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

PSV ventilation strategy

PAV+ ventilation strategy

Arm Description

The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.

The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.

Outcomes

Primary Outcome Measures

Time from randomization to successful liberation from invasive mechanical ventilation.
"Successful liberation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.

Secondary Outcome Measures

Ventilator-free days at 14, 21 and 28 days post randomization
"Ventilator-free days" (VFDs) are defined as the number of days alive and free of INVASIVE ventilation post SUCCESSFUL EXTUBATION or post successful termination of invasive mechanical ventilation (MV) from time of randomization to day 21 post randomization. "Successful extubation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Time from randomization to live ICU discharge (up to day 90)
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Time from randomization to live hospital discharge (up to day 90)
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Mortality
Measured as ICU mortality; hospital mortality; 14, 21, 28, and 90 day mortality
Weaning Progress
Measured as time from randomization to: first SBT; first successful SBT; first extubation
Weaning Difficulties
Measured as the number of patients failing first SBT or first extubation attempt and requiring up to 7 days to extubate (difficult weaning group/group 2); failing first SBT or first extubation attempt and requiring more than 7 days to extubate (prolonged weaning group/group 3)
Weaning Complications
Measured as the number of patients: requiring non-invasive ventilation post-extubation; ventilated more than 7 days post randomization, ventilated more than 21 days from time of intubation (prolonged MV group); receiving tracheostomy post-randomization, requiring re-intubation (up to 7d after planned extubation)
Tolerance of modes
Measured as number of patients ever requiring A/C mode post randomization; number of patient-days requiring A/C mode post randomization
Cumulative dose of narcotics (converted to morphine equivalents); benzodiazepines (converted to midazolam equivalents); propofol, and dexmedetomidine
These are measures of sedation
Number of patients and number of patient-days receiving any antipsychotic medication
This is a surrogate measure of delirium

Full Information

First Posted
May 8, 2015
Last Updated
June 19, 2023
Sponsor
Lawson Health Research Institute
Collaborators
Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group
search

1. Study Identification

Unique Protocol Identification Number
NCT02447692
Brief Title
Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study
Acronym
PROMIZING
Official Title
Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 14, 2016 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lawson Health Research Institute
Collaborators
Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?
Detailed Description
Patients with acute respiratory failure require mechanical ventilation to help them breathe until they recover from their acute illness. Although mechanical ventilation is necessary to sustain life in such situations, it can induce weakness of the respiratory muscles which may lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical ventilation is associated with increased mortality, morbidity and costs to the healthcare system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's respiratory distress while maintaining some respiratory muscle activity. To attain this goal, the amount of ventilator assistance should theoretically be adjusted to target normal or reasonable levels of respiratory effort. Modes of Mechanical Ventilation: Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of mechanical ventilation which delivers assistance to breathe in proportion to the patient's effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient's respiratory effort or workload within a reasonable range. This is the only mode of ventilation which allows for measurement and targeting of a specific range of respiratory muscle activity by the patient. Pressure support ventilation (PSV) is a mode of ventilation which is considered the current standard of care for assisting breathing of patients during the recovery phase of acute respiratory failure. Several studies have shown short term advantages of PAV over PSV, including improved patient-ventilator synchronization, improved adaptability to changes in patient effort, and improved sleep quality. Goal of this Randomized Controlled Trial: To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being more physiological, will result in a shorter duration of time spent on mechanical ventilation than ventilation with PSV.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critically Ill, Acute Respiratory Failure
Keywords
Proportional Assist Ventilation, Pressure Support Ventilation, Weaning

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
573 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PSV ventilation strategy
Arm Type
Active Comparator
Arm Description
The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
Arm Title
PAV+ ventilation strategy
Arm Type
Active Comparator
Arm Description
The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
Intervention Type
Other
Intervention Name(s)
PSV ventilation strategy
Intervention Description
An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
Intervention Type
Other
Intervention Name(s)
PAV+ ventilation strategy
Intervention Description
An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
Primary Outcome Measure Information:
Title
Time from randomization to successful liberation from invasive mechanical ventilation.
Description
"Successful liberation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Time Frame
up to 90 days
Secondary Outcome Measure Information:
Title
Ventilator-free days at 14, 21 and 28 days post randomization
Description
"Ventilator-free days" (VFDs) are defined as the number of days alive and free of INVASIVE ventilation post SUCCESSFUL EXTUBATION or post successful termination of invasive mechanical ventilation (MV) from time of randomization to day 21 post randomization. "Successful extubation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Time Frame
14, 21 and 28 days post randomization
Title
Time from randomization to live ICU discharge (up to day 90)
Description
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Time Frame
up to 90 days
Title
Time from randomization to live hospital discharge (up to day 90)
Description
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Time Frame
up to 90 days
Title
Mortality
Description
Measured as ICU mortality; hospital mortality; 14, 21, 28, and 90 day mortality
Time Frame
up to 90 days
Title
Weaning Progress
Description
Measured as time from randomization to: first SBT; first successful SBT; first extubation
Time Frame
up to 90 days
Title
Weaning Difficulties
Description
Measured as the number of patients failing first SBT or first extubation attempt and requiring up to 7 days to extubate (difficult weaning group/group 2); failing first SBT or first extubation attempt and requiring more than 7 days to extubate (prolonged weaning group/group 3)
Time Frame
90 days
Title
Weaning Complications
Description
Measured as the number of patients: requiring non-invasive ventilation post-extubation; ventilated more than 7 days post randomization, ventilated more than 21 days from time of intubation (prolonged MV group); receiving tracheostomy post-randomization, requiring re-intubation (up to 7d after planned extubation)
Time Frame
90 days
Title
Tolerance of modes
Description
Measured as number of patients ever requiring A/C mode post randomization; number of patient-days requiring A/C mode post randomization
Time Frame
90 days
Title
Cumulative dose of narcotics (converted to morphine equivalents); benzodiazepines (converted to midazolam equivalents); propofol, and dexmedetomidine
Description
These are measures of sedation
Time Frame
90 days
Title
Number of patients and number of patient-days receiving any antipsychotic medication
Description
This is a surrogate measure of delirium
Time Frame
28 days
Other Pre-specified Outcome Measures:
Title
Subgroup analyses based on: (a) duration of MV prior to randomization greater than 5 days
Description
Identifies a subgroup of patients at time of randomization who are at risk for prolonged weaning
Time Frame
90 days
Title
Subgroup analyses based on (b) failing an SBT prior to randomization
Description
Identifies a subgroup of patients at time of randomization classified as difficult weaning vs. failed CPAP 0 trial vs. failed weaning criteria prior to randomization
Time Frame
90 days
Title
Subgroup analyses based on (c) failed extubation prior to randomization
Description
Identifies a subgroup of patients at time of randomization classified as having "difficult weaning".
Time Frame
90 days
Title
Subgroup analyses based on (d) mild vs. moderate vs. severe frailty
Description
Differentiates between severely frail and less frail
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
A staged enrolment process will be used to identify patients eligible to be enrolled and randomized in the study. At each stage of the enrolment process, a patient must meet inclusion criteria and not meet exclusion criteria in order to pass. To progress to the next stage, patients must continue to pass criteria from the prior stages. After enrolment, there are also specific tests to perform (with pass/fail criteria) to determine eligibility to be randomized. A. SCREENING INCLUSION CRITERIA: A1. Age 18 years or older A2. Intubated and receiving any mode of invasive mechanical ventilation ≥ 24 hours A. SCREENING EXCLUSION CRITERIA: A3. Anticipating withdrawal of life support and/or shift to palliation as the goal of care A4. Severe central neurologic disorder (eg. Hemorrhage, stroke, tumour) causing elevated intracranial pressure, or impaired control of breathing, or requiring specific ventilator adjustments (i.e. To attain specific CO2 target) or requiring neurosurgical intervention A5. Known or suspected severe or progressive neuromuscular disorder likely to result in prolonged or chronic ventilator dependence (eg. Guillain-Barré syndrome, Myasthenia Gravis, ALS, MS, high spinal cord injury, kyphoscoliosis or other restrictive disorder) (Note that obesity hypoventilation syndrome that may be managed with nocturnal non-invasive ventilation is NOT an exclusion under A5) A6. Severe COPD: Baseline daytime hypercapnea (pCO2> 50 mmHg) OR GOLD 4 airflow limitation (FEV1<30% predicted) OR MRC class 4 symptoms ("I am too breathless to leave the house" OR "I am breathless when dressing") A7. Broncho-pleural fistula A8. Tracheostomy present at ICU admission for the purpose of chronic or prolonged mechanical ventilation (>21 days). (Note that a patient who was endotracheally intubated for acute respiratory failure and received a tracheostomy during their ICU admission, prior to enrolment, is not excluded under A8). A9. Current enrolment in a confounding study, as assessed by the steering committee A10. Previous randomization in the PROMIZING Study A11. Severe, end-stage, irreversible respiratory or cardiac disease (e.g. interstitial lung disease, pulmonary fibrosis, cardiomyopathy, valvulopathy) likely to result in prolonged or chronic ventilator dependence /unlikely to wean from mechanical ventilation [Note: patients who are candidates for intervention to treat the underlying respiratory/cardiac disease (e.g. lung transplant, heart transplant, cardiac surgery) may be re-evaluated once intervention is complete and they no longer meet criteria A11.] B. ENROLMENT INCLUSION CRITERIA: B1. Ability or potential ability to trigger ventilator breaths (i.e. not receiving neuromuscular blockade). B2. On Assist/Control volume-cycled ventilation: Technically satisfactory plateau pressure ≤ 30 cm H2O (see Operations Manual) OR On Assist/Control pressure-controlled ventilation or similar mode: Pressure control plus PEEP ≤ 30 cm H2O OR On Pressure Support ventilation: Pressure support plus PEEP ≤ 30 cm H2O OR On Proportional Assist ventilation: PAV gain <85% B3. PaO2 ≥ 60 mmHg or SpO2 ≥ 90% on FiO2 ≤ 0.60 and PEEP ≤ 15 cm H2O B4. Metabolic disorders corrected: pH ≥7.32 B5. Stable hemodynamic status: stable or decreasing doses of vasopressors for ≥6 hours B6. Anticipate ongoing need for ventilation >24 hours B. ENROLMENT EXCLUSION CRITERIA: B7. Extubated B8. Died B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% for ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). (Note (1): that it is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients on ECMO.) B10. Patient transferred to a non-participating centre B. ENROLMENT DEFERRAL CRITERIA: B11. Plan to extubate/discontinue mechanical ventilation within <24 hours (Reassess within 24 hours) B12. Patient currently on ECMO (Reassess patient once off ECMO) C9: Plan for surgery or complex procedure that will require full ventilation to be done prior to attempting extubation (e.g. Procedure requiring neuromuscular blockade and/or heavy sedation, such that patient would be apneic, or not be able to trigger ventilator) (Reassess after surgery/procedure complete) C. PRESSURE SUPPORT TRIAL INCLUSION CRITEIRA: C2. Upon review of Screening and Enrolment criteria (A and B), the patient still passes. C3. Treating physician has provided verbal consent to proceed with standardized tests and randomization if eligibility criteria are met. C. PRESSURE SUPPORT TRIAL DEFERRAL CRITERIA: C6. High dose vasopressor requirements (i.e. epinephrine or norepinephrine >0.5 ug/kg/min or equivalent) OR patient requiring an increase in dose of vasopressor within 6 hrs C7. Active cardiac ischemia (dynamic ST changes on monitor or ECG within 6 hours) C8. Unstable arrhythmias (HR>140 or <50) with clinical signs of low cardiac output or or SBP<80 mmHg C10. Receiving a "strict lung protective" ventilation strategy for ARDS (eg. Order on chart to keep Vt ≤6 mL/kg PBW) C. PRESSURE SUPPORT TRIAL EXCLUSION CRITERIA: • C12. Treating physician has declined consent D. WEANING CRITERIA: D1. SpO2≥ 90% on FiO2 ≤0.40 and PEEP ≤8 cmH2O D2. pH ≥7.32 D3. Vasopressor requirements no higher than norepinephrine 0.1 ug/kg/min or equivalent. In the final stage (E), patients will be considered eligible for randomization if the following criteria are met. E. RANDOMIZATION INCLUSION CRITERIA: C1. Patient/SDM has provided consent OR Plan to obtain deferred consent as Patient incapable and no SDM available to provide consent within the randomization window E1. Upon review of Criteria A, B, and C, the patient still passes and the patient has passed the PST. E2. Does not meet Weaning Criteria OR Fails the ZERO CPAP Trial OR Fails the SBT E. RANDOMIZATION EXCLUSION CRITERIA: B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). Note (1): It is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients while on ECMO C4. Patient/SDM has declined consent C5. Patient incapable and no SDM available to provide consent (not applicable if plan to obtain deferred consent) E3. Passed SBT on t-piece, FiO2 0.40 for 30-120 minutes E4. Approval withdrawn (by physician or patient/SDM)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sorcha Mulligan
Phone
416-360-4000
Ext
77049
Email
Sorcha.Mulligan@unityhealth.to
First Name & Middle Initial & Last Name or Official Title & Degree
Karen J Bosma
Phone
519-663-3531
Email
KarenJ.Bosma@lhsc.on.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen J Bosma
Organizational Affiliation
London Health Sciences Centre, London, Ontario, Canada
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Laurent Brochard
Organizational Affiliation
St. Michael's Hospital, Toronto, Ontario, Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
El Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"
City
Buenos Aires
ZIP/Postal Code
C1430EFA
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariano Setten, MD
Email
msetten@yahoo.com
First Name & Middle Initial & Last Name & Degree
Pablo Rodriguez, MD
Facility Name
Royal Columbian Hospital
City
New Westminster
State/Province
British Columbia
Country
Canada
Individual Site Status
Withdrawn
Facility Name
Kingston General Hospital
City
Kingston
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tracy Boyd
Email
Tracy.boyd@kingstonhsc.ca
First Name & Middle Initial & Last Name & Degree
Stephanie Sibley
Facility Name
London Health Sciences Centre - University Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
K.J. Bosma
Phone
519-663-3531
Email
karenj.bosma@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Tracey Bentall
Phone
519-685-8500
Ext
32546
Email
traceyc.bentall@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Karen J. Bosma
Facility Name
Victoria Hospital
City
London
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudio Martin
Email
claudio.martin@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Eileen Campbell
Email
Eileen.Campbell@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Claudio Martin
Facility Name
Sunnybrook Hospital - Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Marinoff
Email
nicole.marinoff@sunnybrook.ca
First Name & Middle Initial & Last Name & Degree
Hamzah Khan
Email
hamzah.khan@sri.utoronto.ca
First Name & Middle Initial & Last Name & Degree
Dr. Andre Carlos Amaral
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Withdrawn
Facility Name
North York General Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Geagea
Email
Anna.Geagea@nygh.on.ca
First Name & Middle Initial & Last Name & Degree
Mary Rahmat
Email
Mary.Rahmat@nygh.on.ca
First Name & Middle Initial & Last Name & Degree
Anna Geagea
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurent Brochard
Email
brochardl@smh.ca
First Name & Middle Initial & Last Name & Degree
Thomas Piraino
Email
pirainot@smh.ca
First Name & Middle Initial & Last Name & Degree
Karen Burns
First Name & Middle Initial & Last Name & Degree
Laurent Brochard
Facility Name
UHN- Toronto General Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niall Ferguson
Email
Niall.Ferguson@uhn.ca
Facility Name
UHN- Toronto Western Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth Wilcox
Email
elizabeth.wilcox@uhn.ca
First Name & Middle Initial & Last Name & Degree
Emad Al Azazi
Email
Emad.AlAzazi@uhnresearch.ca
Facility Name
Centre hospitalier de l'Université de Montréal (CHUM)
City
Montréal
State/Province
Quebec
ZIP/Postal Code
GC6R+GW
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katherine Coutu-Beaudry
Email
katherine.coutu-beaudry.chum@ssss.gouv.qc.ca
First Name & Middle Initial & Last Name & Degree
Emmanuel Charbonney, MD
Facility Name
Hôpital du Sacré-Cœur de Montréal
City
Montréal
State/Province
Quebec
Country
Canada
Individual Site Status
Withdrawn
Facility Name
Royal Victoria Hospital
City
Montréal
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jason Shahin
Email
jason.shahin@gmail.com
First Name & Middle Initial & Last Name & Degree
Josie Campisi
Email
josie.campisi@muhc.mcgill.ca
First Name & Middle Initial & Last Name & Degree
Jason Shahin
Facility Name
Institut Universitaire de cardiologie et de pneumologie de Quebec
City
Québec
State/Province
Quebec
Country
Canada
Individual Site Status
Active, not recruiting
Facility Name
Centre Hospitalier Universitaire (CHU) de Angers
City
Angers
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alain Mercat
Email
alain.mercat@univ-angers.fr
First Name & Middle Initial & Last Name & Degree
Laure Masson
Email
lamasson@chu-angers.fr
First Name & Middle Initial & Last Name & Degree
Alain Mercat
Facility Name
Centre Hospitalier Intercommunal de Créteil
City
Créteil
ZIP/Postal Code
QFW8+H5
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tommaso MARAFFI
Email
tommaso.maraffi@chicreteil.fr
Facility Name
Hôpital Henri Mondor (Assistance Publique-Hôpitaux de Paris)
City
Créteil
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume Carteaux
Email
guillaume.carteaux@aphp.fr
First Name & Middle Initial & Last Name & Degree
Guillaume Carteaux
Facility Name
Centre Hospitalier Universitaire (CHU) de Nice
City
Nice
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital Universitaire Pitié-Salpêtrière
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Dres
Email
martin.dres@aphp.fr
First Name & Middle Initial & Last Name & Degree
Alexandre Demoule
Email
alexandre.demoule@aphp.fr
First Name & Middle Initial & Last Name & Degree
Martin Dres
First Name & Middle Initial & Last Name & Degree
Alexandre Demoule
Facility Name
Centre Hospitalier Universitaire (CHU) de Rouen
City
Rouen
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gaetan Beduneau
Email
gaetan.beduneau@chu-rouen.fr
First Name & Middle Initial & Last Name & Degree
Gaetan Beduneau
Facility Name
University Hospital of Heraklion
City
Heraklion
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Katerina Vaporidi
Email
vaporidi@gmail.com
First Name & Middle Initial & Last Name & Degree
Dr. Katerina Vaporidi
Facility Name
University Hospital of Ferrara
City
Ferrara
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Savino Spadaro
Email
savinospadaro@gmail.com
First Name & Middle Initial & Last Name & Degree
Carlo Alberto Volta
First Name & Middle Initial & Last Name & Degree
Savino Spadaro
First Name & Middle Initial & Last Name & Degree
Elizabetta Marangoni
Facility Name
San Giovanni Battista University Hospital
City
Turin
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vito Faneilli
Email
vito.fanelli@unito.it
First Name & Middle Initial & Last Name & Degree
Vito Fanelli
Facility Name
King Abdulaziz Medical City
City
Riyadh
ZIP/Postal Code
11426
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eman Al Qasim
Email
alqasimem@NGHA.MED.SA
First Name & Middle Initial & Last Name & Degree
Dr. Yaseen Arabi
Facility Name
Hospital de Sant Pau
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan Carlos Suarez Montero
Email
jsuarez@santpau.cat
First Name & Middle Initial & Last Name & Degree
Juan Carlos Suarez Montero
First Name & Middle Initial & Last Name & Degree
Jordi Mancebo

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study

We'll reach out to this number within 24 hrs